ImClone Systems
440 Route 22 East
Bridgewater
New Jersey
08807
United States
Tel: 908-541-8000
Website: http://www.imclone.com/
About ImClone Systems
ImClone Systems is a wholly-owned subsidiary of Eli Lilly and Company and part of Lilly’s oncology business unit. Dedicated to changing the world of cancer care, ImClone is developing its robust pipeline of novel monoclonal antibodies to treat a broad range of tumor types. ImClone is headquartered in New Jersey, where it has one of the world’s largest state-of-the-art biologics manufacturing operations, and it has research laboratories in New York City as well as offices in Europe.261 articles about ImClone Systems
-
ImClone Systems to Pay Abbott Laboratories $17.5 Million to End Lawsuit
8/11/2008
-
ImClone Systems Incorporated Issues Statement
8/1/2008
-
Bristol-Myers Squibb Company (JOBS) Offers to Buy ImClone Systems Incorporated (JOBS) for $60 a Share
7/31/2008
-
ImClone Systems Incorporated Reports Second Quarter 2008 Financial Results
7/24/2008
-
ImClone Systems Incorporated to Host Second Quarter 2008 Financial Results Conference Call
7/21/2008
-
ImClone Systems Incorporated's Erbitux Approved for Colorectal Cancer in Japan
7/16/2008
-
ImClone Systems Incorporated Announces Changes in Commercial Organization Leadership
7/14/2008
-
ImClone Systems Incorporated Release: Phase 2 Study Of IMC-A12 for Advanced Soft Tissue Sarcoma Opens for Patient Enrollment
7/7/2008
-
ImClone Systems Incorporated Release: IMC-A12 Plus Temsirolimus Clinical Trial for Advanced Cancer Opens for Patient Enrollment
6/25/2008
-
ImClone Systems Incorporated to Present at the Goldman, Sachs & Co. 29th Annual Global Healthcare Conference
6/6/2008
-
ImClone Systems Incorporated Says Its Cancer Drug Works as Initial Treatment
6/2/2008
-
ImClone Systems Incorporated Appoints Dr. Bernhard Ehmer Senior Vice President and Managing Director, International Operations
6/2/2008
-
Genomic Health, Inc. Announces Results of Initial Studies to Develop Predictive Tests for Targeted Therapies - Results from Gene Identification Studies Presented at American Society of Clinical Oncology
6/2/2008
-
ImClone Systems Incorporated to Host Investor Reception on June 1, 2008 to Discuss Data Presented at the American Society of Clinical Oncology Annual Meeting
5/30/2008
-
ImClone Systems Incorporated Release: Phase I/II Studies of IMC-A12 in Pancreatic Cancer Open for Patient Enrollment
5/20/2008
-
ImClone Systems Incorporated to Present at the 2008 Citi Investment Research Global Health Care Conference
5/19/2008
-
Significant Data on ERBITUX(R) (cetuximab) and ImClone Systems Incorporated Pipeline to Be Presented at American Society of Clinical Oncology 2008 Annual Meeting
5/16/2008
-
ImClone Systems Incorporated Release: ERBITUX(R) (cetuximab) Data Demonstrate Improvements in Response Rate and Progression-Free Survival in Wild Type K-Ras Metastatic Colorectal Cancer Patients in First-Line Setting
5/16/2008
-
ImClone Systems Incorporated Release: Phase II Study of IMC-A12 for Advanced Liver Cancer Opens for Patient Enrollment
5/13/2008
-
ImClone Systems Incorporated to Present at the Bank of America 2008 Healthcare Conference
5/12/2008